Cyclopharm Ltd

CYC.AU

$1.20

Closing

▲1.94%

1D

▼-4.68%

YTD

Market cap

$112.79M

52 week high

$2.06

52 week low

$1.01

Volume

28,814

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$112.79M

Analysts' Rating

BUY

Price Target (Mean)

2.657756853

Total Analysts

1

P/E

Operating Margin

-31.72%

Beta

0.65

Revenue Growth (Annual)

21.84%

52 week high

$2.06

52 week low

$1.01

Div. Yield

0.54%

EPS Annual Growth

0.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Cyclopharm Limited is an Australia-based health technology company. The Company’s principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The Company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. Its subsidiaries include Cyclomedica Europe Limited, Cyclomedica Australia Pty Limited and Cyclomedica Canada Limited.